Search

Author/Creator O'Day, Steven J.

1. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. (17th June 2013)

Authors:
Wolchok, Jedd D.; Hodi, F. Stephen; Weber, Jeffrey S.; Allison, James P.; Urba, Walter J.; Robert, Caroline; O'Day, Steven J.; Hoos, Axel; Humphrey, Rachel; Berman, David M.; Lonberg, Nils; Korman, Alan J.
Journal:
Annals of the New York Academy of Sciences
Issue:
Volume 1291(2013)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. Issue 9 (November 2017)

Authors:
Gangadhar, Tara C.; Hwu, Wen-Jen; Postow, Michael A.; Hamid, Omid; Daud, Adil; Dronca, Roxana; Joseph, Richard; O'Day, Steven J.; Hodi, F.S.; Pavlick, Anna C.; Kluger, Harriet; Oxborough, Romina P.; Yang, Aiming; Gazdoiu, Mihaela; Kush, Debra A.; Ebbinghaus, Scot; Salama, April K.S.
Journal:
Journal of immunotherapy
Issue:
Volume 40:Issue 9(2017:Nov./Dec.)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. Issue 1 (16th August 2016)

Authors:
Amin, Asim; Lawson, David H.; Salama, April K.S.; Koon, Henry B.; Guthrie, Troy; Thomas, Sajeve S.; O'Day, Steven J.; Shaheen, Montaser F.; Zhang, Bin; Francis, Stephen; Hodi, F. Stephen
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 4:Issue 1(2016)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗